Shelby P Ellery

US Patent:

20210299269, Sep 30, 2021

Filed:

May 31, 2019

Appl. No.:

17/059635

Inventors:

- TOKYO, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Tbilisi, GE
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong Xiao - Belmont MA, US

International Classification:

A61K 47/68
C07K 16/32
C07K 16/28
C07K 16/40
A61K 47/60
C07D 405/06
A61P 35/00
G01N 33/50
C07D 313/00
A61K 31/496
A61K 31/365
A61K 39/395
A61K 45/06
A61K 39/00
A61K 9/127
A61K 9/51
C12Q 1/6886
G01N 33/574
C07K 16/30
C07K 16/24

Abstract:

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

US Patent:

20210163456, Jun 3, 2021

Filed:

Apr 8, 2019

Appl. No.:

17/045952

Inventors:

- Tokyo, JP
John WANG - Andover MA, US
Baudouin GERARD - Belmont MA, US
Kenzo ARAI - Ibaraki, JP
Xiang LIU - Winchester MA, US
Guo Zhu ZHENG - Lexington MA, US
Kazunobu KIRA - Ibaraki, JP
Lisa A. MARCAURELLE - Arlington MA, US
Marta NEVALAINEN - Weymouth MA, US
Ming-Hong HAO - Quincy MA, US
Morgan Welzel O'SHEA - Arlington MA, US
Parcharee TIVITMAHAISOON - Boston MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nicholas C. GEARHART - Durango CO, US
Jason T. LOWE - East Bridgewater MA, US
Yoshihiko KOTAKE - Ibaraki, JP
Satoshi NAGAO - Ibaraki, JP
Regina Mikie KANADA SONOBE - Ibaraki, JP
Masayuki MIYANO - Ibaraki, JP
Norio MURAI - Ibaraki, JP
Andrew COOK - Stow MA, US
Shelby ELLERY - Boston MA, US
Atsushi ENDO - Andover MA, US
James PALACINO - Wellesley MA, US
Dominic REYNOLDS - Stoneham MA, US

Assignee:

EISAI R&D MANAGEMENT CO., LTD. - Tokyo

International Classification:

C07D 407/06
C07D 405/14
A61P 35/00
C07D 313/00
C07D 491/107
C07D 487/08
C07D 487/10
A61K 45/06
C07D 405/12
C07D 417/12
C07D 413/12

Abstract:

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

US Patent:

20210101888, Apr 8, 2021

Filed:

Nov 30, 2020

Appl. No.:

17/247117

Inventors:

- Tokyo, JP
Silvia BUONAMICI - Boston MA, US
Thiwanka SAMARAKOON - Westwood MA, US
Sudeep PRAJAPATI - Somerville MA, US
Nathan FISHKIN - Weymouth MA, US
James PALACINO - Wellesley MA, US
Michael SEILER - Belmont MA, US
Ping ZHU - Acton MA, US
Andrew COOK - Stow MA, US
Peter SMITH - Arlington MA, US
Xiang LIU - Winchester MA, US
Shelby ELLERY - Boston MA, US
Dominic REYNOLDS - Stoneham MA, US
Lihua YU - Acton MA, US
Zhenhua WU - Belmont MA, US
Shouyong PENG - Belmont MA, US
Nicholas CALANDRA - Boston MA, US
Megan SHEEHAN - Allston MA, US
Yonghong XIAO - Belmont MA, US

International Classification:

C07D 405/12
A61P 35/00

Abstract:

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.